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Abstract
Cancer is responsible annually for around 27% of all deaths in Spain, 15% of which are
caused by colorectal cancer. This malignancy has increased its incidence considerably over
the past years, which surely impacts global productivity losses. The evaluation of lost pro-
ductivity due to premature mortality provides valuable information that guides healthcare
policies into the establishment of prevention and screening programs. The purpose of this
study was to assess the productivity losses from premature deaths due to colorectal cancer
over a ten year period (2008–2017). The costs derived from premature mortality due to this
highly prevalent cancer were estimated using data on mortality, age- and sex-specific refer-
ence salaries and unemployment rates in Spain via the human capital approach. Between
2008 and 2017, 15,103 persons died per year from colorectal cancer, representing almost
15% of all cancer-related deaths. Annually, 25,333 years of potential productive life were
estimated to be lost on average, 14,992 in males and 10,341 in females. Productivity losses
summed €510.8 million in in 2017, and the cancers of the colon and rectum accounted for
9.6% of cancer-related productivity losses in 2017 in Spain. Colorectal cancer has an impor-
tant weight in terms of productivity losses within the Spanish population, consequently, pre-
vention and early detection programmes should be promoted and implemented to achieve
significant reductions in mortality and productivity losses.
Introduction
Cancer is the second most common cause of death in Europe [1], with 1.93 million people esti-
mated to die from this disease in 2018 [2]. In Spain, cancers rank as the second leading cause
of mortality, being responsible annually for around 27% of all deaths [3], 15% of which were
caused by colorectal cancer. Additionally, while the incidence of certain cancers, as lung cancer
in Spain is decreasing, the incidence of colorectal cancer has maintained an increasing ten-
dency as measured between the years 1993 and 2015, reaching an age-standardised incidence
rate (Europe) of 77.8 in men and 42.0 in women per 100,000 [4]. Colorectal cancer mortality
in Spain increased between 1985 and 2004, with higher increases in males versus females and
in older age groups versus younger ones [5]. Hence, it is of interest to analyse the economic
burden that this cancer type represents for the Spanish society.
To estimate the economic burden of cancer, it is essential to conduct economic evaluations
that will guide healthcare policies and prevention and screening programs. These evaluations
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data were obtained from http://www.ine.es/dyngs/
INEbase/es/categoria.htm?c=Estadistica_P&cid=
1254735976594. The economically active
population survey was found at http://www.ine.es/
dyngs/INEbase/es/operacion.htm?c=Estadistica_
include direct costs (medical and household expenditures, informal care. . .) and indirect costs
(reduced or lost productivity due to morbidity or mortality) of disease [6]. In terms of indirect
costs, one of the most recognised methods for the estimation of the social and economic losses
attributed to a disease is the measurement of disability-adjusted live years (DALYs), where one
DALY is equivalent to one year of healthy life lost [7]. Equally, the years of productive life lost
(YPPLL) can be calculated; which allows an assessment of the productivity losses due to pre-
mature mortality [8]. In the calculation of YPPLL, it is considered that years from death to pro-
jected retirement are lost due to the disease.
In Europe, 50,168,779 DALYs were attributed to cancer in 2016, 11.15% of those to colorec-
tal cancer, and 48,784,557 years of life were lost [7]. Earlier calculations estimated 302,089
YPPLL due to cancer in Spain, with losses around €2.5 billion [9]. The importance of colorec-
tal cancer in Spain has been widely described, given its prevalence within the Spanish popula-
tion; it is also the second cancer responsible for the most number of deaths after lung cancer
[3]. Additionally, a multicentre cross-sectional study in Spain the year 2014 showed that 50%
of the population affected by this cancer were between 65 and 79 years of age, while 30% were
younger than 65 years [10], which has a direct impact on productivity loss calculations.
This study aims to assess the productivity losses derived from premature deaths due to colo-
rectal cancer in Spain within a ten year period.
Materials and methods
Several methods are available for the calculation of the indirect costs of disease. Herein, the
human capital approach was used to measure productivity losses due to colorectal cancer in
Spain. This method estimates the indirect costs that the disease represents for the individual,
family, society or employer via the calculation of the income and productivity of an individual
that are prevented when premature death occurs [11].
Statistics on mortality and salaries were extracted from the Spanish National Statistics Insti-
tute (INE) [12, 13]. The years of potential productive life lost (YPPLL) due to premature mor-
tality from colorectal cancer were estimated by multiplying the number of colorectal cancer-
specific deaths for a given age group by the expected productive years remaining for each
group. Retirement age was fixed at 65 years, the legal age of retirement in Spain. The costs of
premature mortality were estimated using age- and sex-specific annual wages from death age
to age of retirement were used. YPPLL was corrected per age- and gender-specific unemploy-
ment rates and an annual discount rate of 3% was applied to future income values in the base-
line analysis [14]. A sensitivity analysis was conducted considering two alternative discount
rates (0% and 6%) following recommendations for Spain [15, 16].
The same calculations were conducted considering persons dead per all cancers as regis-
tered in the Spanish National Statistics Institute, which includes cancers of the lung, breast,
pancreas, prostate, stomach, liver, bladder, kidney, haematological cancers, cancers of the ner-
vous system, oesophagus, melanoma, cancers of the reproductive system, oral cavity, larynx,
oropharynx, nasopharynx, gallbladder, mesothelioma, thyroid and Kaposi sarcoma. Ethics
committee approval and consent were not required for this study.
Results
Between 2008 and 2017, 15,103 persons died per year from colorectal cancer, summing a total
of 151,032 persons (Table 1). A 3:2 male/female ratio was measured constantly over the years.
Cancer of the colon and rectum represented on average 14.91% of all cancer-related deaths,
and a mean of 18.27% of those deaths were at working age, being this parameter slightly higher
in males. Large fluctuations in the number of deceased individuals have been registered over
PLOS ONE Evaluation of productivity losses due to premature mortality from colorectal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0244375 December 23, 2020 2 / 8
C&cid=1254736176918&menu=resultados&idp=
1254735976595.
Funding: BCN Health Economics & Outcomes
Research SL provided support in the form of
salaries for the author AM, but did not have any
additional role in the study design, data collection
and analysis, decision to publish, or preparation of
the manuscript. The specific roles of these authors
are articulated in the ‘author contributions’ section.
Competing interests: The authors declare no
competing interests. AM employment at BCN
Health does not alter our adherence to PLOS ONE
policies on sharing data and materials.
Abbreviations: DALYs, Disability-adjusted life-
years; INE, Spanish national statistics institute
(Instituto Nacional de Estadı́stica); YPPLL, Years of
potential productive life lost.
the years, yet, overall, a more pronounced increase is measured the first half of the study
period.
In terms of lost productivity, 25,333 YPPLL annually were estimated during the study
period; 24,126 on 2017.
The age distribution of YPPLL per year were analysed for males and females. Premature
mortality due to colorectal cancer accounted for the highest values of YPPLL in the age period
between 50 and 59 years in both males and females (Fig 1), which impacts directly productivity
costs. Contrarily, fewer YPPLL are measured in younger individuals, this can be attributed to
the lower mortality of the disease in this age group versus that in older individuals.
The calculation of losses due to premature mortality was accomplished via the projection of
productivity losses per year to retirement age, adjusting all calculations for age- and sex-spe-
cific annual wages. Three estimations were obtained, a baseline, and two resulting from the
sensitivity analysis. Over the ten-year study period, the estimated losses due to colorectal can-
cer were €5.2 billion, €510.8 million when only considering the year 2017 (Table 2). The sensi-
tivity analysis determined a range of total costs between €5.1 and €5.3 billion.
The percentage of the costs of lost productivity due to colorectal cancer in relation to all
cancers was also calculated. The cancers of the colon and rectum accounted for 9.6% of can-
cer-related productivity losses in 2017 (Table 3). No clear tendencies were observed over time.
Discussion
The estimation of productivity loss provides a general vision of disease burden that is crucial
for resource allocation and establishment of cancer prevention and detection programs [17].
Worldwide, cancer represents one of the major burdens to confront and colorectal cancer con-
tributes increasing this sum [9]. Colorectal cancer is the second leading cancer-related mortal-
ity cause worldwide and also in Spain [3]. In 2017, 9,103 males and 6,307 females died from
this cancer type in this country, with a percentage of deaths at working age that decreased over
the study period; 17.6% of deaths occurred during working age, which impacts labour
productivity.
Estimations of productivity losses due to premature cancer mortality worldwide suggest
annual losses up to hundreds of billions of dollars, with 196.3 million DALYs calculated in
2013 [18]. One study in the United States projected cancer productivity losses that would
increase to $148 billion in 2020 [19]; in the European Union, cancer was estimated to be
Table 1. Indicators of deaths, deaths at working age and years of potential productive life lost (YPPLL) due to colorectal cancer.
Year 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Number of deaths
males 7,987 8,365 8,816 8,994 9,362 9,235 9,260 8,818 9,430 9,103
females 5,829 5,873 6,067 6,388 6,242 6,364 6,216 6,013 6,363 6,307
% of deaths at working age (16–65)
males 20.23 20.43 19.29 19.62 20.12 19.61 19.56 16.58 18.42 18.57
females 17.98 17.18 17.57 17.44 17.83 17.54 16.68 13.35 16.74 16.20
% of colorectal cancer deaths vs. all cancers
males 13.24 12.88 14.25 17.29 8.58 14.51 18.51 13.02 13.75 15.26
females 14.68 15.59 14.76 18.81 1.94 15.11 15.67 13.77 15.23 14.09
YPPLL total 24,732 25,649 25,576 26,457 27,706 26,701 26,484 20,585 25,316 24,126
males 14,103 15,137 14,673 15,535 16,772 15,618 15,908 12,801 14,926 14,450
females 10,629 10,512 10,903 10,922 10,934 11,083 10,576 7,784 10,390 9,676
https://doi.org/10.1371/journal.pone.0244375.t001
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annually responsible for productivity losses between €42.6 and €75.5 billion depending on the
model, with 8–10% of those losses related to colorectal cancer [1, 20].
It may be difficult to compare studies due to methodological variations that have been pre-
viously described [21, 22]; nonetheless, this study results appear comparable to previous Span-
ish and global cancer burden evaluations. Peña-Longobardo et al. measured €2.5 billion in
productivity losses due to cancer in Spain in 2009 [23]; in a direct comparison, our study sug-
gests that up to 22% of those losses could be due to colorectal cancer. A similar study estimated
€2.1 billion in mortality productivity losses for women with breast cancer in Spain in 2014 and
27,633 YPPLL the same year [16], a seemingly elevated figure, partly justified by the prevalence
of breast cancer among women. Similarly, lung cancer was responsible for 36,246 YPPLL in
males and 23,035 YPPLL in females in 2017, and 899 and 284 million euros in losses in males
and females, respectively, in 2017 [24].
The interest of such studies is justified with the formulation of specific measures that aim to
prevent, detect and reduce cancer incidence, and thus its costs. The implementation of colo-
rectal cancer screenings in Spain started in 2005 two years after the European Colorectal Can-
cer Screening recommendation to perform pilot studies was issued [25]. The year 2014 such
programmes were included in reimbursement lists and covered by the National healthcare sys-
tem [26], which has allowed to increase colorectal cancer detection rates. Such screenings are
aimed at the population aged 50 to 69 years, and even though only 43.92% of target individuals
participated in the screening programmes in 2011, overall participation rates follow an increas-
ing tendency over time [27]. Cancer detection rate was 2.3% in 2012 and 72.2% of cancers
were detected in early stages, which validates the utility of screenings allowing early detection
and subsequent treatment [27]. Still, the prevalence of this cancer and the productivity losses
derived make evident the need to increase participation rates, especially among males, also
considering the long-term costs that are derived from its treatment [28]. Direct medical costs
linked to colorectal cancer reach figures around the €41,550 per patient in long-term costs for
patients in stage III [28]. In addition, estimates point out that an annual 1% reduction in can-
cer mortality would decrease productivity losses by €8.5 billion over 20 years [29].
Equally, the promotion of healthier behaviours is recommended aiming to decrease colo-
rectal cancer incidence, as regular physical activity, the consumption of fibre, fruits and vegeta-
bles, folate, calcium, vitamin D, vitamin B6 and magnesium [30].
Fig 1. Years of potential productive life lost (YPPLL) due to premature mortality from colorectal cancer per age groups between 2008
and 2017 in males (a) and females (b).
https://doi.org/10.1371/journal.pone.0244375.g001
Table 2. Productivity losses (in millions) due to colorectal cancer (a 3% discount rate was used in the baseline analysis; 0% and 6% discount rates were used in the
sensitivity models).
Year Productivity losses (baseline 3%) Productivity losses (0%) Productivity losses (6%)
2008 555.6 560.8 541.6
2009 548.5 553.5 534.7
2010 531.9 536.5 518.5
2011 540.3 545.0 526.7
2012 550.5 555.6 536.7
2013 515.5 519.8 502.6
2014 516.5 521.1 503.5
2015 416.1 419.2 405.7
2016 520.1 524.4 507.0
2017 510.8 514.6 498.0
Total 5,205.8 5,250.4 5,075.1
https://doi.org/10.1371/journal.pone.0244375.t002
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It is plausible that a number of limitations may have influenced the results of this study.
The lack of data on disease incidence in both males and females over the study period has lim-
ited data interpretation. The human capital approach is the majority method used for the cal-
culation of indirect costs of disease via productivity losses, although it presents a series of
restrictions. The assumption that future earnings translate into productivity has been ques-
tioned, together with the consideration that productivity lost is not covered by another indi-
vidual [6].
Conclusions
Altogether, the productivity costs due to colorectal cancer mortality have been evaluated and
updated. Deaths from colorectal cancer represented almost 15% of all cancer-related deaths,
with 25,333 YPPLL estimated annually and accounting for €510.8 million in productivity
losses in 2017. This data underlines the burden of colorectal cancer on the Spanish population,
providing novel data on death number, trends and productivity losses that this cancer type
represents. This may assist decision makers in the allocation of resources, prioritising early




Formal analysis: Alicia Marsà.
Investigation: Alicia Marsà.
Methodology: Alicia Marsà.




Writing – original draft: Alicia Marsà.
Writing – review & editing: Josep Darbà.
Table 3. Percentage of productivity losses (in millions) due to colorectal cancer vs. all cancers (a 3% discount rate was used in the baseline analysis; 0% and 6% dis-
count rates were used in the sensitivity models).
Year % productivity losses (baseline 3%) % productivity losses (0%) % productivity losses (6%)
2008 10.1 9.9 10.1
2009 9.4 9.3 9.4
2010 12.5 12.3 12.5
2011 9.5 9.3 9.5
2012 13.0 12.8 13.0
2013 12.7 12.4 12.7
2014 10.1 9.9 10.1
2015 8.0 7.9 8.0
2016 10.6 10.5 10.6
2017 9.6 9.5 9.6
https://doi.org/10.1371/journal.pone.0244375.t003
PLOS ONE Evaluation of productivity losses due to premature mortality from colorectal cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0244375 December 23, 2020 6 / 8
References
1. Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: the cost of lost productiv-
ity due to premature cancer-related mortality in Europe. Int J Cancer. 2015 Feb 15; 136(4):E136–45.
https://doi.org/10.1002/ijc.29105 PMID: 25066804
2. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortal-
ity patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018
Nov; 103:356–87. https://doi.org/10.1016/j.ejca.2018.07.005 PMID: 30100160
3. Spanish Society of Medical Oncology. Cancer data in Spain. [Sociedad Española de Oncologı́a Médica.
Las cifras del cáncer en España]. https://seom.org/dmcancer/wp-content/uploads/2019/Informe-
SEOM-cifras-cancer-2019.pdf Accessed April 2019.
4. Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain,
2015. Clin Transl Oncol. 2017 Jul; 19(7):799–825. https://doi.org/10.1007/s12094-016-1607-9 PMID:
28093701
5. Ribes J, Navarro M, Clèries R, Esteban L, Pareja L, Binefa G, et al. Colorectal cancer mortality in Spain:
trends and projections for 1985–2019. Eur J Gastroenterol Hepatol. 2009 Jan; 21(1):92–100. https://
doi.org/10.1097/MEG.0b013e32830b5f39 PMID: 19011574
6. Jo C. Cost-of-illness studies: concepts, scopes and methods. Clin Mol Hepatol. 2014 Dec; 20(4):327–
37. https://doi.org/10.3350/cmh.2014.20.4.327 PMID: 25548737
7. World Health Organization. Health statistics and information systems. https://www.who.int/healthinfo/
global_burden_disease/en/ Accessed April 2019.
8. Schofield D, Shrestha RN, Cunich MM, Tanton R, Veerman L, Kelly SJ, et al. Economic costs of chronic
disease through lost productive life years (PLYs) among Australians aged 45–64 years from 2015 to
2030: results from a microsimulation model. BMJ Open. 2016 Sep 22; 6(9):e011151. https://doi.org/10.
1136/bmjopen-2016-011151 PMID: 27660315
9. Oliva-Moreno J. Loss of labour productivity caused by disease and health problems: what is the magni-
tude of its effect on Spain’s economy? Eur J Health Econ. 2012 Oct; 13(5):605–14. https://doi.org/10.
1007/s10198-011-0344-9 PMID: 21858534
10. Esteva M, Ruiz A, Ramos M, Casamitjana M, Sánchez-Calavera MA, González-Luján L, et al. Age dif-
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